<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00145808</url>
  </required_header>
  <id_info>
    <org_study_id>13215A</org_study_id>
    <nct_id>NCT00145808</nct_id>
  </id_info>
  <brief_title>Wireless Capsule Endoscopy in Ulcerative Colitis</brief_title>
  <official_title>Prospective Controlled Assessment of Wireless Capsule Endoscopy (WCE) in Ulcerative Colitis (UC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prometheus Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <brief_summary>
    <textblock>
      Based on the inaccuracies of the current classification scheme for inflammatory bowel disease&#xD;
      (IBD), the failure of surgical pouches and the findings of retrospective observational trials&#xD;
      to date, we hypothesize that a significant proportion of patients with UC will have small&#xD;
      bowel involvement that will result in a change in diagnosis to CD or the recognition of a new&#xD;
      phenotype of IBD. The aim of this study is to determine the prevalence of small bowel&#xD;
      pathology in patients diagnosed with UC using WCE. This information will aid in the current&#xD;
      efforts to re-classify IBD using improved endoscopic and imaging technologies, genetic&#xD;
      information and serologic information.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will undergo both a blood draw and a wireless capsule endoscopy (WCE).&#xD;
&#xD;
      The blood draw will occur in the GI procedure unit on the day of subjects exam.&#xD;
&#xD;
      WCE: Subject will only consume a clear liquid diet after noon the day prior to the exam. No&#xD;
      food or beverage consumption any after 10 PM on the day before examination. Not oral&#xD;
      medications after 12 AMon the day of exam (8 hours before subject's exam).&#xD;
&#xD;
      Day of exam, subject will report to the endoscopy unit. At that time, subject will be&#xD;
      prepared for examination by doctor who will apply a sensor array to the abdomen with adhesive&#xD;
      sleeves. In addition, a waist belt device that holds the data recorder will be fitted to&#xD;
      subject. Subjects will swallow the capsule endoscope. The capsule endoscope passes naturally&#xD;
      through digestive tract while transmitting video images to the data recorder worn on the belt&#xD;
      for approximately eight hours. At this point, subjects will be free to leave the University&#xD;
      of Chicago hospital until they return eight hours later for disconnection of the recording&#xD;
      equipment.&#xD;
&#xD;
      Two hours after ingestion of the capsule, subject will be able to resume a clear liquid diet.&#xD;
      Four hours after the study's start time, subject will be able to resume a regular diet (&#xD;
      solid foods). At this time, subject will also be able to resume taking oral medications.&#xD;
&#xD;
      After eight hours, subject will return to the endoscopy suite (DCAM 6H) for disconnection of&#xD;
      the recording equipment (sensor array, data recorder, and belt). The time that the capsule&#xD;
      was ingested, eating and drinking times, and disconnection time as well as any discomfort&#xD;
      subject experienced will be recorded.&#xD;
&#xD;
      Subject will be contacted 72 hours after the examination to confirm passage of the capsule.&#xD;
      If they have not reported passage of the capsule with this time, subject will undergo an&#xD;
      abdominal radiograph in order to determine whether or not the capsule has passed.&#xD;
&#xD;
      Subjects will be asked to identify a non-relative control (spouses are acceptable) within&#xD;
      five years of their age and of similar background without Ulcerative Colitis. There is an&#xD;
      Information Handout that participating subjects will give to friends interested in&#xD;
      participating. If the subject does not find anyone, they may still participate in this&#xD;
      research study. The study staff will try to find someone for them.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the prevalence of small bowel abnormalities in UC patients compared to controls.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ensure safety of subjects by confirming passage of the capsule.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GivenÂ® Diagnostic System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for the &quot;disease&quot; arm include a clinical impression of ulcerative&#xD;
        colitis that includes assessment of the colon by colonoscopy and biopsy and assessment of&#xD;
        the terminal ileum either by ileoscopy or by small bowel radiograph or enteroclysis.&#xD;
        Subjects in the &quot;control&quot; arm will only be included if they do not carry the diagnosis of&#xD;
        UC or CD, have not had previous gastric or small bowel surgery and are free of&#xD;
        gastrointestinal symptoms including unexplained abdominal pain, diarrhea or&#xD;
        gastrointestinal bleeding.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A known bowel obstruction, fistula or stricture, a permanent pacemaker and/or implantable&#xD;
        defibrillator, history of a swallowing disorder, inability to provide informed consent,&#xD;
        pregnancy, the use of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) within the&#xD;
        past 30 days, known celiac disease, known terminal ileal disease on ileoscopy and a history&#xD;
        of occult or obscure gastrointestinal bleeding of unclear etiology. In menstruating&#xD;
        females, a urine HCG will be performed on the day they arrive for the study (prior to&#xD;
        ingestion of the capsule), if fourteen (14) days or more have elapsed since their last&#xD;
        menstrual period. If subject reports they are menopausal, a urine HCG will be performed&#xD;
        unless subject has had no menses during the past two years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulcerative colitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

